Adverse effects: any serious, specific ‐ dystonia during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: any serious, specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ cardiovascular ‐ hypotension · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ cardiovascular ‐ hypotension compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Adverse effects: specific ‐ seizure · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ central nervous system ‐ seizures compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: specific ‐ dystonia · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects: specific ‐ dystonia compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
Global outcome: specific Not sedated at 60 minutes * · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: specific Not sedated at 60 minutes * compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ Aggression ‐ no overall improvement · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes specific behaviour ‐ aggression ‐ no overall improvement compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes specific behaviour ‐ threat or injury to self or others compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ dystonia during 24 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ injury or threat of self to others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: Specific ‐ hypotensive episode · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effect: Specific ‐ hypotensive episode compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review
Specific behaviours ‐ agitation >50% reduction in PANSS‐EC score · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in specific behaviours ‐ agitation >50% reduction in PANSS‐EC score compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ EPS during 24 hours · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects: Specific ‐ EPS during 24 hours compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (low certainty).
1 finding from 1 review
Adverse effects: specific ‐ acute dystonia · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ acute dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: Specific ‐ hypotensive episode · patients with psychosis‐induced aggression or agitation
1 finding from 1 review